Fate Therapeutics Inc (NASDAQ:FATE) Expected to Announce Quarterly Sales of $2.07 Million

Equities research analysts expect that Fate Therapeutics Inc (NASDAQ:FATE) will report sales of $2.07 million for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Fate Therapeutics’ earnings. The highest sales estimate is $3.00 million and the lowest is $630,000.00. Fate Therapeutics reported sales of $2.63 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 21.3%. The firm is scheduled to issue its next earnings report on Tuesday, May 5th.

On average, analysts expect that Fate Therapeutics will report full year sales of $8.60 million for the current fiscal year, with estimates ranging from $4.00 million to $12.00 million. For the next fiscal year, analysts anticipate that the business will report sales of $7.25 million, with estimates ranging from $2.50 million to $13.00 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Fate Therapeutics.

Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings data on Monday, March 2nd. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.02. Fate Therapeutics had a negative return on equity of 49.94% and a negative net margin of 919.00%. The business had revenue of $2.80 million for the quarter, compared to analyst estimates of $1.70 million. During the same period in the previous year, the company posted ($0.25) earnings per share. The firm’s revenue for the quarter was up 68.7% on a year-over-year basis.

FATE has been the subject of several research analyst reports. BMO Capital Markets boosted their price objective on shares of Fate Therapeutics from to in a research report on Tuesday, March 3rd. Guggenheim upped their target price on shares of Fate Therapeutics from $25.00 to $41.00 and gave the stock a “buy” rating in a research note on Tuesday, March 3rd. Barclays began coverage on shares of Fate Therapeutics in a research note on Wednesday, March 4th. They set an “overweight” rating and a $40.00 price objective for the company. Wedbush raised their target price on shares of Fate Therapeutics from $29.00 to $33.00 and gave the company an “outperform” rating in a research note on Friday, February 14th. Finally, BidaskClub cut shares of Fate Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, March 18th. Four equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Fate Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $33.94.

In other news, insider Bahram Valamehr sold 5,700 shares of the business’s stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $20.69, for a total value of $117,933.00. Following the sale, the insider now owns 91,758 shares of the company’s stock, valued at $1,898,473.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO J Scott Wolchko sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $25.45, for a total transaction of $636,250.00. Following the completion of the sale, the chief executive officer now directly owns 444,969 shares in the company, valued at approximately $11,324,461.05. The disclosure for this sale can be found here. 23.19% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Meeder Asset Management Inc. raised its position in shares of Fate Therapeutics by 46.1% in the fourth quarter. Meeder Asset Management Inc. now owns 2,029 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 640 shares during the period. ProShare Advisors LLC boosted its stake in shares of Fate Therapeutics by 4.0% during the fourth quarter. ProShare Advisors LLC now owns 24,569 shares of the biopharmaceutical company’s stock valued at $481,000 after purchasing an additional 942 shares during the period. California State Teachers Retirement System boosted its stake in shares of Fate Therapeutics by 1.2% during the third quarter. California State Teachers Retirement System now owns 81,518 shares of the biopharmaceutical company’s stock valued at $1,266,000 after purchasing an additional 974 shares during the period. New York State Common Retirement Fund boosted its stake in shares of Fate Therapeutics by 1.9% during the fourth quarter. New York State Common Retirement Fund now owns 54,600 shares of the biopharmaceutical company’s stock valued at $1,069,000 after purchasing an additional 1,000 shares during the period. Finally, Vident Investment Advisory LLC boosted its stake in shares of Fate Therapeutics by 1.6% during the fourth quarter. Vident Investment Advisory LLC now owns 81,695 shares of the biopharmaceutical company’s stock valued at $1,599,000 after purchasing an additional 1,274 shares during the period. 95.07% of the stock is currently owned by institutional investors.

Shares of FATE traded down $0.09 on Monday, hitting $23.31. The company’s stock had a trading volume of 834,442 shares, compared to its average volume of 1,120,458. The company has a market capitalization of $1.81 billion, a PE ratio of -16.30 and a beta of 1.71. The company has a debt-to-equity ratio of 0.10, a current ratio of 8.17 and a quick ratio of 8.17. Fate Therapeutics has a fifty-two week low of $12.59 and a fifty-two week high of $32.39. The company has a 50 day moving average price of $26.65 and a 200 day moving average price of $20.14.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system.

Recommended Story: When is a capital gain realized?

Get a free copy of the Zacks research report on Fate Therapeutics (FATE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.